spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

ICON Announces Executive Leadership Transition

ICON plc

Global provider of services to pharma and biotech industries announces the appointment of Mr Ciaran Murrry to Chairman of the Board of Directors, and Dr Steve Cutler as CEO

  • Mr. Ciaran Murray to transition to Chairman, effective 1st March 2017
  • Dr. Steve Cutler to be appointed Chief Executive Officer, effective 1st March 2017
Dublin, Ireland, October 20, 2016 – ICON plc, a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that, as part of its planned succession of executive leadership, Mr. Ciaran Murray will transition to the role of Chairman of the Board of Directors and Dr. Steve Cutler will be appointed as Chief Executive Officer, with both changes effective as of 1st March 2017.

Dr. Cutler joined ICON in 2011 as President, ICON Clinical Research Services. He was promoted to ICON plc Chief Operating Officer in January 2014 and was appointed to the Board of Directors in November 2015. “Steve will bring significant industry experience and proven leadership capabilities to the role of Chief Executive Officer” said Mr. Declan McKeon, acting Chairman of the Board. “As Chief Operating Officer, Steve has strengthened and expanded our global operations and he is well placed to lead the company to continued growth and success. The Board is happy to have such a strong internal successor to take over from Ciaran now that he has decided to transition to the role of chairman”.

Commenting on his appointment Dr. Cutler added “I am pleased and excited to be appointed as ICON’s Chief Executive Officer. I look forward to continuing to work with Ciaran and the rest of the Board during the transition period and beyond. ICON has a strong management team and together we will remain focused on enhancing our position as the CRO partner of choice in drug development. Also, I would like to personally thank Ciaran for his leadership of ICON over the last five years.”

Prior to joining ICON, Dr. Cutler was Chief Executive Officer of Kendle. Prior to Kendle, Dr. Cutler held various senior roles in both Quintiles and Sandoz (now Novartis). Dr. Cutler holds a B.Sc. and a Ph.D from the University of Sydney and a Masters of Business Administration from the University of Birmingham (UK).

Mr. McKeon also thanked Mr. Murray for his leadership of the company. “Since 2011, Ciaran has led ICON through a transformative phase of our development which has seen the company deliver outstanding financial and operational performance and broaden its strategic capabilities. Ciaran has also been an excellent partner for the Board and we are delighted that he has accepted our offer to transition to the role of Chairman of the Board of Directors.”

Mr. Murray commented “The last five years as ICON’s CEO have been the most exciting and fulfilling of my professional career. Since I took over as Chief Executive Officer, five years ago the company has made significant progress. Through our focus on innovation, investment in talent and by continuing to enhance and broaden our service capabilities we have driven significant growth and shareholder value. During this time, we have developed a strong management team and with ICON well positioned for the future the time is right for me to step down as Chief Executive Officer and for Steve to take over leadership of ICON. I look forward to continuing to work with Steve and the rest of the Board in my new role as Chairman.”
phone +353 1 291 2883
email info-clinical@iconplc.com
web www.iconplc.com
email ICON plc, Headquarters, South County Business Park, Leopardstown, Dublin 18, Ireland
 
Print this page
Send to a friend
   
spacer
News and Press Releases

NDA Group Releases Data Comparing FDA and EMA Ahead of Annual DIA Europe in Basel

Today NDA Group announced their findings from its fifth annual comparison of drug approvals in Europe and the United States, in preparation for this year’s DIA Europe in Basel, Switzerland. The figures highlight the continued differences between the two regions, and the need for a global approach to drug development to ensure success across both continents.
More info >>


White Papers

The Flexible Factory Concept: A flexible bioprocessing platform to meet the changing needs of biomanufacturing

GE Healthcare Life Sciences

For the past several years, the biopharma industry has been buffeted by dynamic market conditions that are rapidly reshaping manufacturing requirements. These factors include: • The rise of small-market pharmaceuticals that do not require the production scale of the previous “blockbuster” drug model • Increased titers and process productivity that generate more bulk-product within a much smaller manufacturing footprint • The emergence of biosimilars and continued evolution of healthcare reform, which will increasingly pressure drug pricing and require greater cost discipline • Greater competition and shorter patent protection timelines, which will further ratchet up time-to-market pressures • Tighter capital markets that will create heightened scrutiny for all new investment projects
More info >>

Industry Events

ChinaBio Partnering Forum 2018

25-26 April 2018, Kempinski Hotel Suzhou, Jiangsu, China

Access a world of opportunities through life science partnering in China. ChinaBio® Partnering Forum is the premier life science partnering event in China. The conference will be held April 25–26 in Suzhou, attracting biotech and pharma leaders from around the world along with hundreds of China-based developers of novel technologies for two days of productive partnering.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement